# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

#### **SCHEDULE 13G**

Under the Securities Exchange Act of 1934 (Amendment No. )\*

### Tarsus Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share (Title of Class of Securities)

87650L 103 (CUSIP Number)

**December 31, 2020** (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAMES OF REPORTING PERSONS						
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	Perceptive Advisors LLC						
2							
2	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) □ (b) □						
3	SEC USE ONLY						
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION						
	D 1						
	Delaware	-	COVE VOTING POLITE				
		5	SOLE VOTING POWER				
N	UMBER OF	6	SHARED VOTING POWER				
DE	SHARES	O	SHARED VOTING POWER				
	NEFICIALLY WNED BY		1,296,416				
	EACH	7	SOLE DISPOSITIVE POWER				
R	EPORTING	,	SOLE DISTOSITIVE TOWER				
	PERSON		0				
	WITH:	8	SHARED DISPOSITIVE POWER				
			1,296,416				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	1,296,416						
10							
11	□ I PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9						
11	PERCENT (	JF C	LASS REFRESENTED DI AMUUNT IN KUW S				
	6.4%						
12	2 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
<u> </u>	IA						

1	NAMES OF REPORTING PERSONS						
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	Joseph Edelman						
2			DDDODDIATE DOV IE A MEMDED OF A CDOUD (SEE INSTRUCTIONS)				
2	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) □ (b) □						
3	SEC USE ONLY						
4	CITIZENSH	IIP (	OR PLACE OF ORGANIZATION				
	United States of America						
		5	SOLE VOTING POWER				
N	UMBER OF		0				
	SHARES	6	SHARED VOTING POWER				
BE	NEFICIALLY						
C	WNED BY		1,296,416				
	EACH	7	SOLE DISPOSITIVE POWER				
K	EPORTING PERSON						
	WITH:	8	0 SHARED DISPOSITIVE POWER				
	,,,,	Ö	SHARED DISPOSITIVE POWER				
			1,296,416				
9							
	1 200 410						
10	1,296,416 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
10	CHECK BO	ЛΠ	THE AGGREGATE AMOUNT IN ROW (3) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11	PERCENT (	OF C	CLASS REPRESENTED BY AMOUNT IN ROW 9				
	6.4%						
12							
	IN						

1	NAMES OF REPORTING PERSONS						
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	Perceptive Life Sciences Master Fund, Ltd.						
2							
2	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) □ (b) □						
3	SEC USE ONLY						
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION						
	Cayman Isla						
		5	SOLE VOTING POWER				
N	UMBER OF		0				
	SHARES	6	SHARED VOTING POWER				
	NEFICIALLY		1 200 410				
C	WNED BY EACH	7	1,296,416  SOLE DISPOSITIVE POWER				
REPORTING		/	SOLE DISPOSITIVE POWER				
10	PERSON		0				
	WITH:	8	SHARED DISPOSITIVE POWER				
			1,296,416				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
	1,296,416						
10							
4.1	DEDCEME	)F (	N. ACC DEPONDED BY AMOUNT IN DOLLA				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9						
	6.4%						
12							
<u> </u>	CO						

#### Item 1(a). Name of Issuer:

Tarsus Pharmaceuticals, Inc. (the "Issuer")

#### Item 1(b). Address of Issuer's Principal Executive Offices:

15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618

#### Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the "Reporting Persons") are:

Perceptive Advisors LLC ("Perceptive Advisors")

Joseph Edelman ("Mr. Edelman")

Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")

#### Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor New York, NY 10003

#### Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company

Mr. Edelman is a United States citizen

The Master Fund is a Cayman Islands corporation

#### Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, \$0.0001 par value per share ("Common Stock")

#### Item 2(e). <u>CUSIP Number</u>:

87650L 103

#### Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

#### Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 20,320,426 outstanding shares of Common Stock, as reported in the Issuer's Form 10-Q filed on November 25, 2020.

The Master Fund directly holds 1,296,416 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.

#### Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following  $\Box$ .

#### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

## Item 7. <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.</u>

Not applicable.

#### Item 8. <u>Identification and Classification of Members of the Group</u>.

Not applicable.

#### Item 9. <u>Notice of Dissolution of Group.</u>

Not applicable.

#### Item 10. <u>Certification</u>.

Not applicable.

#### **SIGNATURE**

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 16, 2021

PERCEPTIVE ADVISORS LLC

By: <u>/s/ J</u>oseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

#### AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: February 16, 2021

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member